Hongbiao X. Huang

Key Laboratory Of Protein Modification And Degradation, State Key Laboratory Of Respiratory Disease
Guangzhou, 511436, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Corrigendum to Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling EBioMedicine, Volume 43, (2019), Pages 188-200. doi: 10.1016/j.ebiom.2019.04.001.

Corrigendum to Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling EBioMedicine, Volume 43, (2019), Pages 188-200. doi: 10.1016/j.ebiom.2019.04.001.

Journal: EBioMedicine
Published: April 04, 2026

The GCN5L2-SIX1 complex drives glycolysis to promote progression of triple-negative breast cancer.

The GCN5L2-SIX1 complex drives glycolysis to promote progression of triple-negative breast cancer.

Journal: Cancer letters
Published: February 27, 2026

HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15.

HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15.

Journal: Oncogene
Published: January 19, 2026

The RPS15-DDX21 complex drives prostate malignancy through transcriptional activation of SCD1.

The RPS15-DDX21 complex drives prostate malignancy through transcriptional activation of SCD1.

Journal: Oncogene
Published: November 06, 2025

CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.

CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.

Journal: Breast cancer research : BCR
Published: March 19, 2025

WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression.

WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression.

Journal: Oncogene
Published: February 26, 2025

Ku70 targets BRD3-MYC/Cyclin D1 axis to drive hepatocellular carcinoma progression.

Ku70 targets BRD3-MYC/Cyclin D1 axis to drive hepatocellular carcinoma progression.

Journal: Experimental cell research
Published: September 27, 2024

METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy.

METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy.

Journal: Pharmacological research
Published: September 21, 2024

The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.

The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.

Journal: Oncogene
Published: July 23, 2024

SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration.

SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration.

Journal: Cellular & molecular biology letters
Published: April 11, 2024

HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.

HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 29, 2023

USP14 inhibition promotes recovery by protecting BBB integrity and attenuating neuroinflammation in MCAO mice.

USP14 inhibition promotes recovery by protecting BBB integrity and attenuating neuroinflammation in MCAO mice.

Journal: CNS neuroscience & therapeutics
Published: January 04, 2023
Showing 1-12 of 69

Last Updated: 09/26/2026